Premedication With Atenolol Versus Metoprolol for Controlled Hypotensive Anesthesia During Nasal Surgeries

Premedication With Atenolol Versus Metoprolol for Controlled Hypotensive Anesthesia During Nasal Surgeries. A Randomized Clinical Trial

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04914234

Enrollment

Registered

2021-06-04

Start date

2025-08-01

Completion date

2026-01-30

Last updated

2025-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypotension Drug-Induced

Keywords

atenolol, controlled hypotension, metoprolol, nasal surgery

Brief summary

Objectives: To compare the safety and efficacy of oral atenolol versus oral metoprolol as a premedication for controlled hypotensive anesthesia during nasal surgeries. Background: Mucosal bleeding is the most frequent complication with nasal surgeries, as it interferes with the optimal visualization of the intranasal anatomy, increases operation time, and consequently increases blood loss. There are several pharmacological and non-pharmacological techniques for the appropriate control of intraoperative bleeding. Patients and Methods: This was a prospective, randomized, double-blind, phase four, comparative clinical trial; carried out on 60 patients, who were candidates for nasal surgeries under general anesthesia at our hospital. Patients were randomly allocated into two equal groups; group A, received oral atenolol, and group M, received oral metoprolol.

Interventions

DRUGAtenolol Succinate Oral Tablet

Atenolol 50 mg

DRUGMetoprolol Succinate Oral Tablet

Metoprolol 100 mg

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

21 Years to 50 Years

Healthy volunteers

Inclusion criteria

* American Society of Anesthesiologists (ASA) physical status ≤ II * Age from 21 to 50 years

Exclusion criteria

* ASA physical status \> II * Age \< 21 years or \> 50 years * Pregnant women * Breastfeeding * Bronchial asthma * Chronic obstructive pulmonary disease * Diabetes Mellitus * Hypertension * Ischemic heart disease * Rheumatic heart disease * Heart failure * Heart block * Sick sinus syndrome * Sinus bradycardia * Chronic hypotension * Anemia (Hb \< 10 g/dl) * Renal or hepatic dysfunction * Central nervous system disease * Allergic fungal sinusitis * Patients on beta-blockers * Alcohol or drug abuse * Anticoagulation therapy, * Bleeding diathesis * Agents influencing autonomic nervous system * Allergy to the study drugs * Any contraindication of oral intake

Design outcomes

Primary

Measure	Time frame	Description
Mean and Standard deviation of Blood loss (ml)(mean±SD)	5 minutes after the end of surgery	Amount of blood loss at the end of surgery

Countries

Egypt

Contacts

Primary ContactAhmed M Shaat, MD

ahmedshaat99@gmail.com00201223482709

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026